CLOV241004C6000
- 0.01
- -0.02-66.67%
Clover Health Newsroom
CCORF Maintains Clover Health(CLOV.US) With Buy Rating, Raises Target Price to $3.2
Cautious Optimism Amidst Clover Health's Strong Quarter: A Hold Recommendation With Revised Price Target
Buy Rating Affirmed for Clover Health on Strong Commercial Potential of Clover Assistant Technology
Cautious Optimism Tempered by Sustainability Concerns: Analyst Upholds Hold Rating on Clover Health Investments
Clover Health's Positive Trajectory: A Buy Rating With a Focus on Sustained Profitability
Analysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)
Clover Health Investments: Hold Rating With High Risk Amidst Progress Towards Stability
Analysts' Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV) and Biomea Fusion (BMEA)
Hold Rating on Clover Health Investments: Performance Upsides, Growth Concerns, and Capital Risk Factors
Hold Rating on Clover Health: Mixed Financial Performance and Future Uncertainty
Citigroup Maintains Neutral on Clover Health Investments, Raises Price Target to $1.5
Clover Health Investments Analyst Ratings
Clover Health Investments (CLOV) Receives a Sell From Bank of America Securities
SVB Securities Remains a Hold on Clover Health Investments (CLOV)
Clover Health Investments (CLOV) Gets a Sell From Bank of America Securities
Clover Health Investments (CLOV) Gets a Sell From Bank of America Securities
Credit Suisse Maintains Underperform on Clover Health Investments, Lowers Price Target to $1.25
Clover Health Investments (CLOV) Receives a Hold From SVB Securities
Credit Suisse Trims Clover Health Investments' Price Target to $2.50 From $3, Lowers 2022 to 2024 Revenue Estimatesl; Keeps Underperform Rating
SVB Securities Adjusts Price Target on Clover Health Investments to $1.50 From $3, Maintains Market Perform Rating